Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4890 - Identification of patients who benefit from apatinib in advanced gastric cancer: data derived from a real world study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Jifeng Feng

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

J. Feng1, B. Shen2, H. Jiang3, L. Wang4, J. Qian5, Y. Shu6, P. Chen7, G. Mao8, B. Liu9, X. Zhang10, C. Liu11, J. Wu12, X. Li13, W. Cai14, W. Shen15, Q. Wang16, J. He17, D. Hua18, Z. Zhang19, Y. Zhang20

Author affiliations

  • 1 Department Of Oncology, Jiangsu Cancer Hospital, 210009 - Nanjing/CN
  • 2 Department Of Oncology, Jiangsu Cancer Hospital, Nanjing/CN
  • 3 Department Of Oncology, Changzhou No.2 People’s Hospital, Changzhou/CN
  • 4 Department Of Oncology, Bayi Hospital of People's Liberation Army, Nanjing/CN
  • 5 Department Of Oncology, Suzhou Municipal Hospital, Suzhou/CN
  • 6 Department Of Oncology, Jiangsu Province hospital, Nanjing/CN
  • 7 Department Of Oncology, Yancheng City No.1 People’s Hospital, Yancheng/CN
  • 8 Department Of Oncology, Affiliated Hospital Of Nantong University, Nantong/CN
  • 9 Department Of Oncology, Nanjing Drum Tower Hospital, Nanjing/CN
  • 10 Department Of Oncology, Northern Jiangsu People's Hospital, Yangzhou/CN
  • 11 Department Of Oncology, Wuxi People's Hospital, Wuxi/CN
  • 12 Department Of Oncology, The First People's Hospital of Changzhou, Changzhou/CN
  • 13 Department Of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang/CN
  • 14 Department Of Oncology, The First People's Hospital of Wujiang, Wujiang/CN
  • 15 Department Of Oncology, The First People's Hospital of Kunshan, Kunshan/CN
  • 16 Department Of Oncology, Jiangyin People's Hospital, Jiangyin/CN
  • 17 Department Of Oncology, Huai'an First People's Hospital, Huai'an/CN
  • 18 Department Of Oncology, Affiliated Hospital, Jiangnan University, Wuxi/CN
  • 19 Department Of Oncology, Changshu No.2 People’s Hospital, Changshu/CN
  • 20 Department Of Oncology, Jiangning People's Hospital, Nanjing/CN
More

Resources

Abstract 4890

Background

A prospective, multicenter, non-intervention registered study of apatinib is being conducted in advanced gastric cancer patients (pts). The result of interim analysis on efficacy and safety was released in ESMO 2017 Congress (695P). Herein, we mainly aimed to identify pts who benefit from apatinib treatment.

Methods

Pts with advanced or metastatic adenocarcinoma of stomach or gastro-esophageal junction who received apatinib administration were included in this real world study. The subgroup analyses were stratified by numbers of metastatic sites, ECOG PS, dosage of apatinib, and occurrence of adverse events (AEs).

Results

As of January 2018, data on 321 pts were available for final analysis. The median progression free survival (mPFS) and median overall survival (mOS) were 4.0 mos and 8.2 mos, respectively. 239 pts (74.5%) reported AEs. Main AEs were proteinuria (17.1%), hypertension (15.9%), and hand-foot syndrome (8.7%). As in table, the mPFS and mOS of pts with ≤2 metastatic sites were longer than those of pts with >2 metastatic sites (mPFS: p = 0.0087, mOS: p = 0.0006). For pts with ECOG PS 0, 1, and ≥2, the differences among groups were significant (mPFS, p < 0.001; mOS, p = 0.0316). Among different dose groups, dose ≥500 mg got longer mPFS (p < 0.001) and mOS (p = 0.0059). What’s more, pts who reported proteinuria, hypertension, hand-foot syndrome, or leukopenia had longer mPFS (ps < 0.05) and mOS (ps < 0.05) compared with those who didn't.Table: 682P

Prognostic factors associated with apatinib treatment

nmPFS, mospmOS, mosp
Metastatic site≤21995.00.00879.10.0006
>2674.06.6
ECOG PS0805.7<0.0018.70.0316
11684.38.2
≥2733.06.6
Dosage, mg2501113.4<0.0017.70.0059
5001874.59.5
>500235.011.8
ProteinuriaNo2663.60.00038.00.0035
Yes555.69.2
HypertensionNo2703.6<0.0018.00.0212
Yes516.08.8
Hand-foot syndromeNo2933.80.00158.0<0.001
Yes286.211.3
LeukopeniaNo2613.5<0.0017.7<0.001
Yes607.39.6

Conclusions

The real world study confirms that apatinib is safe and effective for advanced gastric cancer pts. Factors associated with better prognosis were ≤2 metastatic sites, ECOG PS 0/1, dose ≥500 mg, and occurrence of proteinuria, hypertension, hand-foot syndrome, or leukopenia.

Clinical trial identification

ChiCTR-OPN-15006601, release date June 11, 2015.

Legal entity responsible for the study

Jiangsu Cancer Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

There is no editorial assistance.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.